lyophilized tirzepatide UPB Tirz 10MG (Box of 10, Double Agonist) GLP-2 TZ

GLP-1 450-750 GLP-1 - 1 2 T2D 450-750 GLP-1 30%-50% 20351500 GLP-1 20%-25% 30%-50% 450-750 GLP-1 2025 danuglipron orforglipron 20 + GLP-1 6 / Kailera15 + GLP-1 + HDM1002 HRS-7535 III orforglipron 1-2 Regor RGT-075 I/II 10%-30% GLP-1 1 GLP-1 BD 120+ GLP-1 III 6 HRS-7535/HRS-9531 NewCo HS-10535 2025 SYH2086 Madrigal2026 20 15+ HDM1002 III IBI3032 I TQF3250 IND BD Regor RGT-075 IIb 202512 2 BD + GLP-1 2030 61%34%2024-2025 4 - - GLP-1 orforglipron 188.8 137.65 / 2 GLP-1 1 orforglipron orforglipronIII 36mg 72 T2D 9.1%-11.5% 10.3% 25mgIII 64 11% 7% HRS-7535180mg 36 BMI 32.5 37-39 8.0%Regor RGT-075125mg IIa 12 5.0% 2 / + MindRank MDR-001240mg 43.8% HRS-7535180mg 43.8% orforglipron10.3% Regor RGT-075 danuglipronScaffold B Scaffold B HDM1002 800 2026 I 3 - + orforglipron OSAIII / T2D HRS-7535 + HFpEFII Scaffold B GLP-1 Scaffold Aorforglipron Scaffold Bdanuglipron Scaffold B HDM1002 Scaffold A 10%-30% orforglipron danuglipron - Kailera - FTO GLP-1 III 17.5% 20.9% CDMO GLP-1 1 600276.SS/1276.HK NewCo HRS-7535/HRS-9531 6 B 19.9% + royalties III 2026 180mg 8.0% 3692.HKHS-10535 2025 HS-10501 II 2026 II 1093.HKSYH2086 Madrigal2026 + MASH Madrigal 2 BD000963.SZHDM1002 GLP-1 III 2026 Scaffold B GLP-1/GIP DR10624MASH II 1801.HKIBI3032 I preclinical 5-10 2026 I BD 1177.HKTQF3250orforglipron IND2026 I / T2D 3CDMO GLP-1 CDMO 2269.HK CDMO 23 GLP-1 24%2025 TIDES / 142% GLP-1 GLP-1 30%-40% III danuglipron 2025 12 Regor RGT-075 IIb 2026 / III Scaffold A 2027 GLP-1 50%+ GLP-1 GLP-1 450-750 III / I CDMO 2025 12 Regor IIb 2026 / III ()

If pen needles are not included, ask the pharmacist to provide you with an adequate supply of needles

In 2024, Barton LLP achieved favorable outcomes in two lawsuits brought by Novo Nordisk, the behemoth pharmaceutical company and maker of the blockbuster weight-loss drugs Ozempic and Wegovy

www.facebook.com